While it is not known whether these benefits apply to people with type 1 diabetes, the potential for A1c reductions, weight loss, lower blood pressure, and flatter glucose profiles could make the drug an appealing option for many people
For long-term in vitro study, murine primary chondrocytes were stimulated with 2 ng/mL IL-1 and treated with 50 nM of liraglutide at 37C and 5% CO 2 for 72 h
Liraglutide also carries warnings about pancreatitis, liraglutide pen sharing, hypoglycemia when used in conjunction with certain other drugs known to cause hypoglycemia including insulin and sulfonylurea, renal impairment or kidney failure, hypersensitivity and acute gallbladder disease
Galindo is supported in part by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institute of Health (NIH) under award numbers P30DK111024, 1K23DK123384, 1R03DK138255, and 1U2CDK137135